The board-approved leadership transition takes effect on January 1, 2027, subject to final shareholder approval. Shekhar Bajaj will maintain his involvement with the business solely through a non-executive board seat and his role as a shareholder. The corporate reorganization follows a sharp financial recovery, moving from an annual loss to profitability within the current fiscal period. Investors welcomed the governance update, sending company stock higher on the BSE.
Key points
The leadership changes require shareholder approval to formally enact the proposed corpor…: The leadership changes require shareholder approval to formally enact the proposed corporate governance shift.
The company is pivoting toward a professionally managed and board-led governance model.: The company is pivoting toward a professionally managed and board-led governance model.
Market confidence responded favorably to the transition as company shares climbed 3.53 pe…: Market confidence responded favorably to the transition as company shares climbed 3.53 percent to Rs 291.50.
Sources checked by our analysis pipeline: 1
Bajaj will become a non-executive member of the board, subject to shareholder approvals, from January 1, 2027, an official statement said.
The company's board approved the transition as part of an evolution in leadership and a shift to a professionally managed and board-led governance model, it said.
Sudarshan Sampathkumar, who is serving as an independent director, has been appointed non-executive chairman from January 2027, subject to shareholder approval.
Sanjay Sachdeva will continue to lead the company as the managing director and chief executive, it said.
"I believe this is the right time to evolve our governance model and allow the Board to play an even stronger collective role," Bajaj said, adding that he is committed to the company as a shareholder.
Sampathkumar thanked the board for the confidence placed in him, and committed to encouraging constructive dialogue as the company enters its next phase.
The company reported a loss of Rs 77.26 crore in FY26, but it seems to be swinging back into the black with a Rs 73.25 crore net profit in the first half of FY27.
Strong commercial performance from the company's leading weight-loss medication has triggered another upward revision to its financial guidance. Surging adoption across the United States reflects sustained appetite for effective prescription treatments in the metabolic healthcare sector. This commercial momentum solidifies the drugmaker's leadership position in an increasingly competitive pharmaceutical market.
Rapidly accelerating query traffic is no longer translating into proportional ad sales as users pivot toward artificial intelligence alternatives, sparking a steep sell-off in extended trading. Massive infrastructure spending to deploy proprietary chips and models compounded the earnings shortfall, driving free cash flow far below market expectations. Meanwhile, robust enterprise demand across the cloud division provided a vital counterweight to the core business slowdown.
Investment firm Gordon Brothers is pursuing insolvency proceedings after turning down a comprehensive rescue bid from Martin Property Group in favor of a potentially more lucrative breakup. The formal filing provides a brief ten-day reprieve from creditors for the 600-store chain, which operates across the UK and Ireland under both the Poundland and Dealz brands. While widespread store closures threaten thousands of retail staff, several rival budget chains are already circling to acquire selected physical locatio…